tori
syncyti
viru
rsv
parainfluenza
viru
herp
simplex
small
proport
case
acut
bronchiti
nonvir
etiolog
mycoplasma
pneumonia
bordetella
pertussi
chlamydia
pneumonia
taiwan
acut
respiratori
war
strain
recogn
bacteri
caus
acut
bronhiti
etiolog
role
streptococcu
pneumonia
haemophilu
influenza
acut
bronchiti
clear
bacteria
may
repres
resid
flora
upper
respiratori
tract
normal
individu
examin
role
secondari
bacteri
infect
pathogenesi
acut
bronchiti
necessari
obtain
sampl
tracheobronchi
tree
without
contamin
nasopharyng
acut
tracheobronch
may
also
consequ
inhal
irrit
toxic
substanc
result
air
pollut
occup
exposur
ammonia
chlorin
sulfur
dioxid
nitrogen
dioxid
loo
acut
bronchial
infect
mucou
membran
tracheobronchi
tree
hyperem
edemat
increas
bronchial
secret
common
featur
although
extens
destruct
respiratori
epithelium
may
seen
influenza
viral
agent
rhinoviru
caus
minim
epitheli
n
jr
impair
mucociliari
function
seen
patient
infect
even
without
overt
mucos
determin
pathogenesi
acut
tracheobronch
complic
sever
factor
studi
seek
infecti
caus
frequent
fail
isol
specif
pathogen
delay
seek
medic
care
onset
symptom
may
bring
patient
medic
attent
beyond
period
viral
shed
may
one
explan
determin
caus
agent
complic
patient
chronic
lung
diseas
may
tracheobronchi
colon
potenti
pathogen
bacteria
includ
h
influenza
pneumonia
moraxella
catarrhali
increas
serum
antibodi
titer
bacteria
associ
acut
bronchit
symptom
suggest
bacteria
may
caus
although
analysi
antibodi
coat
bacteria
sputum
addit
sever
attack
acut
bronchiti
may
increas
exposur
cigarett
smoke
air
pollut
substanc
associ
recurr
acut
bronchial
infect
may
result
perman
injuri
bronchial
tree
epidemiolog
studi
support
potenti
role
acut
respiratori
infect
pathogenesi
chronic
obstruct
lung
relationship
acut
bronchiti
heighten
airway
reactiv
also
studi
extens
increas
airway
reactiv
airway
resist
usual
manifest
bothersom
cough
may
persist
elev
airway
resist
observ
bronchial
infect
larg
revers
psympathomimet
anticholinerg
bronchodil
cough
uniformli
found
patient
acut
bronchiti
may
product
mucoid
purul
sputum
cough
may
accompani
variabl
amount
hemoptysi
retrostern
pain
often
describ
burn
sensat
usual
accentu
inspir
gener
temperatur
minim
moder
elev
physic
examin
often
show
harsh
breath
sound
rhonchi
variabl
amount
expiratori
wheez
occasion
focal
area
diminish
breath
sound
present
suggest
inspiss
mucu
caus
atelectasi
atelectasi
may
reliev
use
humidifi
bronchodil
vigor
cough
need
tracheal
suction
sometim
diffus
diminut
air
intak
inspiratori
stridor
present
find
indic
obstruct
major
bronchi
trachea
viral
acut
tracheobronch
run
benign
selflimit
cours
howev
herp
simplex
type
associ
sever
febril
tracheobronch
respiratori
failur
normal
immunocompet
adultslw
bronchiti
may
suspect
patient
acut
respiratori
tract
infect
associ
cough
howev
bronchiti
must
consid
diagnosi
exclus
seriou
diseas
lower
respiratori
tract
associ
cough
complet
histori
includ
inform
exposur
toxic
substanc
cigarett
use
epidemiolog
consider
vaccin
histori
thorough
physic
examin
essenti
exclud
caus
cough
includ
cardiovascular
parenchym
lung
diseas
routin
bacteri
cultur
expector
sputum
help
sampl
problem
contamin
nasopharyng
flora
usual
technic
difficulti
cpllect
transport
interpret
adequ
lower
respiratori
tract
sampl
occasion
natur
sputum
may
provid
diagnost
clue
instanc
except
adenoviru
infect
sputum
viral
infect
almost
alway
show
mark
predomin
mononuclear
cell
gram
wright
stain
contrast
bacteri
infect
sputum
show
predomin
polymorphonuclear
leukocyt
mycoplasma
infect
usual
associ
mononuclear
cell
predomin
polymorphonuclear
cell
popul
may
present
cultur
method
microimmunofluoresc
test
develop
laboratori
diagnosi
c
pneumoniu
use
gamma
immunoglobulin
specif
conjug
help
detect
current
infect
patient
cough
persist
beyond
expect
durat
acut
ill
diagnost
examin
includ
chest
radiographi
sputum
cytolog
bronchoscopi
exclud
diseas
tracheobronchi
tree
lung
case
acut
bronchiti
symptomat
treatment
need
howev
patient
underli
chronic
cardiopulmonari
diseas
contract
influenza
sever
form
bronchiti
may
develop
seriou
symptom
requir
hospit
oxygen
therapi
ventilatori
assist
cough
suppress
adequ
hydrat
prevent
dri
bronchial
secret
symptomat
treatment
mild
fever
malais
associ
influenzalik
syndrom
cornerston
treatment
acut
bronchiti
otherwis
healthi
individu
bronchospast
symptom
domin
may
role
inhal
p
adrenerg
bronchodil
valu
antibiot
treatment
otherwis
healthi
individu
acut
bronchiti
establish
use
agent
recommend
gener
practic
uncertainti
stem
conflict
result
clinic
trial
may
explain
base
variat
type
antibiot
dosag
schedul
durat
followup
season
year
reflect
preval
differ
pathogen
lack
placebocontrol
design
mani
studi
factor
may
prompt
use
antibiot
includ
patient
age
signific
underli
medic
ill
sever
persist
eg
week
durat
symptom
circumst
treatment
tetracyclin
macrolid
cover
suspect
pathogen
pneumonia
c
pneumonia
pneumonia
epidem
known
caus
influenza
viru
treatment
amantidin
recommend
patient
suspect
influenza
ill
less
hour
durat
chronic
obstruct
lung
diseas
afflict
popul
fourth
lead
caus
death
unit
iz
acut
bronchiti
acut
exacerb
chronic
bronchiti
aecb
frequent
encount
gener
famili
physician
account
approxim
million
physician
visit
per
year
chronic
bronchiti
airflow
obstruct
found
men
women
tecumseh
michigan
populationbas
survey
unit
kingdom
one
fourth
primari
care
visit
relat
respiratori
diseas
half
caus
upper
lower
respiratori
tract
bronchiti
associ
million
lost
work
day
death
per
year
unit
approxim
million
prescript
given
lower
respiratori
tract
infect
account
million
million
europ
lower
respiratori
tract
infect
treat
physician
differenti
acut
bronchiti
acut
exacerb
chronic
bronchiti
communityacquir
pneumonia
viral
respiratori
tract
infect
pattern
antibiot
prescrib
infect
vari
countri
countri
rational
antimicrobi
choic
exist
chronic
obstruct
pulmonari
diseas
copd
progress
diseas
character
reduc
expiratori
airflow
rel
stabl
sever
month
chronic
bronchiti
defin
clinic
excess
cough
product
sputum
day
least
month
least
consecut
year
major
risk
factor
chronic
bronchiti
cigarett
smoke
cumul
smoke
histori
close
relat
symptom
factor
implic
develop
chronic
bronchiti
includ
occup
environment
exposur
eg
dust
air
pollut
sulfur
dioxid
nitrogen
dioxid
childhood
respiratori
tract
passiv
smoke
may
also
risk
factor
chronic
bronchiti
evid
suggest
less
clear
prognosi
copd
affect
lung
function
reflect
forc
expiratori
volum
second
fev
fall
predict
fevl
fall
l
surviv
rate
approxim
poor
correl
exist
amount
sputum
produc
degre
airflow
frequent
acut
exacerb
bronchiti
associ
acceler
declin
acut
exacerb
chronic
obstruct
lung
diseas
usual
defin
episod
respiratori
decompens
without
object
document
caus
pneumonia
role
bacteri
infect
acut
exacerb
chronic
bronchiti
controversi
mani
patient
treat
antibiot
whether
treatment
efficaci
debat
sever
group
demonstr
increas
number
bacteria
neutrophil
sputum
causal
relationship
infer
appear
acut
antibodi
respons
serum
bacteria
increas
inflammatori
mediat
purul
relationship
bacteri
infect
symptom
complic
high
spontan
remiss
rate
expect
bacteri
exacerb
usual
limit
bronchial
mucosa
landmark
studi
anthonisen
coworkersg
demonstr
first
time
patient
could
stratifi
accord
symptom
predict
respons
antimicrobi
therapi
patient
least
two
increas
dyspnea
sputum
volum
sputum
purul
broadspectrum
antibiot
eg
amoxicillin
trimethoprimsufamethoxazol
doxycyclin
lead
improv
clinic
outcom
fewer
therapeut
failur
rapid
rate
lung
function
recoveri
compar
placebo
overal
length
ill
day
shorter
antibiotictr
group
compar
group
receiv
placebo
metaanalysi
nine
random
placebocontrol
trial
patient
treat
antibiot
acut
exacerb
chronic
bronchiti
conclud
small
statist
signific
clinic
physiolog
improv
could
expect
antibiotictr
ss
mc
tabl
demonstr
result
seven
nine
trial
recent
complet
larg
random
placebocontrol
italian
trial
includ
metaanalysi
benefici
impact
antibiot
demonstr
studi
includ
largest
number
patient
six
trial
report
peak
expiratori
flow
rate
improv
lmin
favor
antibiot
group
note
although
improv
small
may
clinic
relev
particularli
patient
limit
respiratori
reserv
design
flaw
earlier
studi
small
number
studi
patient
unclear
select
criteria
uncertain
microbiolog
nonstandard
evalu
criteria
lack
stratif
patient
may
account
discrep
outcom
bacteri
pathogen
isol
sputum
patient
aecb
h
infuenza
commonli
isol
organ
sputum
log
coloni
count
organ
magnitud
associ
ventilatorassoci
pneumonia
suggest
signific
bacteri
load
exacerb
caus
endogen
exogen
reinfect
h
infuenza
persist
infect
patient
keep
h
infuenza
strain
longer
period
antibiot
therapi
may
effect
erad
h
patient
aecb
appear
relationship
sever
underli
pulmonari
diseas
sputum
bacteriolog
eller
coworkersm
observ
declin
lung
function
preval
enter
gramneg
organ
pseudomona
increasesm
h
parainuenza
isol
sputum
mani
patient
acut
exacerb
chronic
bronchiti
coloni
count
high
x
cfuml
sputum
cultur
serum
antibodi
respons
suggest
potenti
role
organ
true
respiratori
pathogen
plactamas
mediat
amoxicillin
resist
seen
h
infenza
strain
north
america
europ
almost
catarrhati
unit
state
survey
conduct
demonstr
highlevel
resist
concern
observ
strain
demonstr
multipl
drug
resist
ygml
cigarett
smoke
common
caus
chronic
mucociliari
system
form
primari
defens
mechan
respiratori
tract
inhal
particl
includ
bacteria
viral
infect
cigarett
smoke
frequent
damag
cili
ted
epithelium
turn
impair
mucociliari
mucociliari
function
may
also
reduc
increas
mucou
volum
alter
mucou
rheolgi
viral
infect
result
releas
inflammatori
mediat
kinin
increas
local
permeabl
may
predispos
respiratori
mucosa
bacteri
colon
loss
larg
area
ciliat
epithelium
occur
viral
bacteri
infect
contribut
impair
mucociliari
learanc
delay
mucociliari
clearanc
afford
bacteria
opportun
multipli
attach
first
mucou
mucos
organ
uniqu
design
take
advantag
nontyp
h
infuenza
express
pili
piliat
isol
nontyp
ij
influenza
adher
human
nasopharyng
epitheli
cell
well
organ
h
infuenza
produc
substanc
impair
ciliari
function
stimul
mucou
product
destroy
local
immunoglobulin
impair
phagocyt
function
damag
tracheobronchi
epithelium
h
influenm
synthes
histamin
releas
uncharacter
factor
impair
human
neutrophil
bacteria
loiter
airway
host
inflammatori
respons
stimul
movement
larg
number
neutrophil
subsequ
releas
proteinas
toxic
oxygen
radic
mucou
product
epitheli
surfac
damag
may
enhan
neutrophil
attract
chemoattract
bacteri
produ
c
proteinas
enzym
elastas
releas
neutrophil
found
sputum
patient
chronic
progress
airway
damag
may
occur
product
bacteria
host
respons
bacteria
local
host
defens
may
impair
lead
evergreat
chanc
bacteri
colon
thu
damag
process
term
viciou
circl
hypothesi
may
account
insidi
progress
airway
patient
signific
compromis
lung
function
may
develop
acut
respiratori
failur
consequ
acut
exacerb
therefor
prudent
identifi
highrisk
popul
aggress
approach
appli
outset
hope
avoid
import
complic
mechan
ventil
requir
patient
long
expens
intens
care
unit
icu
care
hospit
mortal
rate
factor
report
associ
inhospit
mortal
includ
age
year
comorbid
respiratori
nonrespiratori
organ
dysfunct
hospit
length
stay
icu
patient
age
sever
airway
obstruct
patient
copd
identifi
major
determin
surviv
patient
follow
year
discharg
hospit
factor
link
surviv
perform
statu
use
oral
corticosteroidsllo
follow
institutiob
antibiot
therapi
acut
exacerb
chronic
bronchiti
factor
predict
failur
initi
antimicrobi
therapi
return
prescrib
physician
treatment
need
hospit
includ
coexist
cardiopulmonari
diseas
number
previou
presenc
cardiovascular
comorbid
four
exacerb
previou
year
sensit
specif
predict
return
prescrib
physician
treatment
advanc
age
signific
impair
lung
function
poor
perform
statu
comorbid
condit
histori
previou
frequent
exacerb
requir
system
corticosteroid
medic
character
high
risk
group
patient
cost
failur
treatment
patient
high
aggress
approach
treatment
highrisk
group
may
improv
outcom
routin
antimicrobi
therapi
fail
exacerb
therapeut
failur
lead
increas
cost
care
extra
physician
visit
diagnost
test
repeat
cours
antibiot
may
also
lead
hospit
prolong
absenc
work
stratif
patient
risk
categori
may
allow
physician
select
target
antimicrobi
therapi
prevent
consequ
approach
becom
increasingli
import
increas
rate
resist
standard
antimicrobi
therapi
sever
stratif
scheme
propos
improv
initi
antimicrobi
select
balter
cowork
canada
suggest
patient
could
categor
five
tabl
group
acut
simpl
bronchiti
like
viral
induc
previou
respiratori
problem
antimicrobi
therapi
recommend
group
patient
persist
symptom
week
durat
macrolid
treat
suspect
pathogen
neumonia
c
pneumoni
nm
ne
recommend
group
patient
simpl
chronic
bronchiti
minim
impair
pulmonari
function
without
risk
factor
treatment
recommend
anthonisen
demonstr
benefici
effect
antibiot
aminopenicillin
suggest
firstlin
therapi
acut
exacerb
consequ
treatment
failur
expect
rel
group
patient
describ
moder
sever
chronic
bronchiti
may
elderli
year
like
frequent
exacerb
four
moreyear
treatment
antibiot
direct
toward
plactamaseproduc
strain
h
injluenza
catarrhali
secondor
thirdgener
cephalosporin
trimethoprimsulfamethoxazol
amoxicillinclavulan
acid
secondgener
macrolid
quinolon
suggest
group
similar
group
signific
comorbid
ill
congest
heart
failur
diabet
mellitu
chronic
renal
failur
chronic
liver
diseas
treatment
regimen
similar
suggest
group
advis
group
patient
classifi
bronchiectasi
sputum
cultur
recommend
group
tailor
therapi
isol
pathogen
lode
propos
patient
divid
three
tabl
firstdegre
patient
defin
rel
short
durat
chronic
bronchiti
rare
exacerb
normal
lung
function
infect
usual
pathogen
name
h
injluenza
pneumonia
suggest
antimicrobi
choic
group
includ
oral
amoxicillin
doxycyclin
cotrimoxazol
macrolid
seconddegre
patient
defin
longer
histori
chronic
obstruct
lung
diseas
sever
exacerb
year
impair
lung
function
concern
gramneg
pathogen
lode
propos
use
oral
cephalosporin
amoxicillinclavulan
acid
quinolon
thirddegre
patient
describ
hospit
patient
signific
comorbid
prolong
histori
copd
sever
function
impair
frequent
infect
gramneg
pathogen
suggest
oral
therapi
cephalosporin
amoxicillinclavulan
acid
quinolon
hospit
patient
drug
administ
intraven
aminoglycosid
combin
plactam
antibiot
recommend
unit
kingdom
wilsonl
classifi
patient
four
group
tabl
group
patient
acut
bronchiti
usual
viral
origin
underli
lung
diseas
present
group
ill
usual
selflimit
run
benign
cours
group
patient
simpl
chronic
bronchiti
younger
mild
moder
impair
lung
function
fevl
predict
valu
less
four
exacerb
per
year
group
patient
typic
pathogen
includ
h
influenm
pneurnonia
r
rz
present
although
viral
infect
often
preced
bacteri
superinfect
treatment
lactam
usual
success
prognosi
excel
group
patient
older
may
poor
underli
lung
function
predict
altern
may
demonstr
moder
impair
lung
function
fevi
predict
signific
comorbid
eg
diabet
mellitu
congest
heart
failur
chronic
renal
diseas
chronic
liver
diseas
experi
four
exacerb
per
year
h
infuenza
pneumonia
catarrhali
continu
predomin
organ
group
patient
initi
treatment
failur
major
implic
patient
healthcar
system
includ
increas
time
lost
work
hospit
treatment
medic
direct
toward
resist
organ
quinolon
amoxicillinclavulan
acid
secondor
thirdgener
cephalosporin
secondgener
macrolid
perform
better
amoxicillin
group
patient
suffer
chronic
bronchial
infect
frequent
exacerb
character
increas
spu
tum
product
increas
sputum
purul
cough
worsen
dyspnea
mani
patient
evid
bronchiectasi
subject
highresolut
ct
scan
individu
tend
chronic
progress
cours
aggress
therapeut
approach
offer
addit
usual
respiratori
organ
gramneg
organ
includ
enterobacteriacea
pseudomona
spp
consid
potenti
pathogen
ciprofloxacin
agent
activ
speci
consid
agent
choic
identifi
classif
system
emphas
identifi
highrisk
popul
treat
outset
antibiot
design
deal
potenti
resist
organ
approach
may
reduc
risk
treatment
failur
especi
highrisk
popul
signific
medic
econom
implic
recent
complet
studi
patient
least
three
treat
exacerb
past
year
class
patient
random
receiv
either
ciprofloxacin
nonquinolonebas
therapi
next
acut
exacerb
chronic
bronchiti
prospect
health
econom
studi
clinic
endpoint
ie
day
ill
hospit
time
next
exacerb
blend
qualityoflif
measur
nottingham
health
profil
st
georg
hospit
respiratori
questionnair
health
util
index
total
respiratori
cost
societ
perspect
although
overal
result
indic
prefer
either
treatment
arm
patient
risk
factor
ie
sever
underli
lung
diseas
four
exacerbationsyear
durat
bronchiti
year
elderli
signific
comorbid
ill
use
ciprofloxacin
led
improv
clinic
outcom
higher
qualiti
life
lower
cost
result
studi
suggest
aggress
antimicrobi
therapi
direct
especi
toward
resist
organ
highrisk
patient
may
effect
strategi
therapi
therapi
older
antimicrobi
effect
particularli
lactamasproduc
h
j
nu
e
n
treatment
acut
exacerb
chronic
bronchiti
fall
two
gener
approach
prevent
symptomat
therapi
smoke
cessat
identifi
major
cornerston
manag
patient
chronic
bronchiti
recent
lung
health
confirm
smoke
cessat
greatli
reduc
rate
declin
fevl
benefit
smoke
cessat
seen
even
patient
age
chronic
sputum
product
often
clear
within
week
smoke
nicotinereplac
therapi
effect
approach
smoke
cessat
although
counsel
physician
shown
potent
interent
annual
influenza
vaccin
reduc
morbid
mortal
influenza
elderli
benefici
effect
believ
result
prevent
airway
epitheli
damag
predispos
subsequ
bacteri
infect
caus
viru
benefici
effect
pneumococc
vaccin
patient
chronic
bronchiti
firmli
establish
howev
current
recommend
patient
copd
receiv
pneumovax
valent
pneumococc
vaccin
least
live
consider
given
repeat
vaccin
everi
year
especi
highrisk
patient
rapid
declin
pneumococc
antibodi
level
orcel
coworkersxb
show
reduct
incid
acut
exacerb
chronic
bronchiti
oral
immun
lyophil
fraction
eight
common
pathogen
isol
respiratori
tract
random
doubleblind
placebocontrol
trial
present
time
howev
oral
vaccin
patient
chronic
bronchiti
remain
experiment
approach
gener
combin
inhal
anticholinerg
inhal
pagonist
use
treatment
acut
exacerb
chronic
bronchiti
oxygen
therapi
maintain
pq
mm
hg
arteri
oxygen
satur
may
requir
excess
use
oxygen
avoid
may
lead
progress
hypercapnia
either
decreas
hypox
ventilatori
drive
worsen
ventilationperfus
mismatch
within
lung
aminophyllin
acut
exacerb
chronic
bronchiti
add
littl
bronchodil
potenti
inhal
medic
increas
side
retrospect
review
patient
present
emerg
room
acut
exacerb
copd
show
clear
benefit
group
treat
albert
report
faster
improv
pulmonari
function
test
random
placebocontrol
doubleblind
clinic
trial
parenter
corticosteroid
acut
exacerb
copd
result
current
system
corticosteroid
copd
exacerb
sccope
clinic
trial
conduct
veteran
affair
medic
research
servic
better
defin
role
oral
corticosteroid
current
weight
clinic
evid
support
use
cours
system
corticosteroid
manag
acut
exacerb
chronic
bronchiti
bronchiti
acut
chronic
form
recurr
acut
exacerb
one
common
reason
physician
visit
account
signific
cost
healthcar
system
lost
work
day
increas
morbid
mortal
smoke
recurr
lower
respiratori
tract
infect
major
risk
factor
chronic
bronchiti
therefor
smoke
cessat
vaccin
strategi
cornerston
manag
term
halt
diseas
progress
reduc
frequenc
infecti
exacerb
bacteri
infect
main
culprit
acut
flare
diseas
routin
antimicrobi
therapi
fail
signific
number
patient
therapeut
failur
lead
increas
cost
sever
stratif
scheme
propos
improv
initi
antimicrobi
select
scheme
identifi
patient
age
sever
underli
pulmonari
dysfunct
frequenc
exacerb
presenc
comorbid
ill
predictor
like
pathogen
guid
antimicrobi
seiection
approach
may
reduc
risk
treatment
failur
would
signific
medic
econom
implic
improv
understand
role
airway
inflamm
infect
pathogenesi
progress
airway
diseas
addit
futur
studi
examin
efficaci
newer
class
antimicrobi
guid
physician
target
earli
effect
treatment
highrisk
patient
